TP53, tumor protein p53, 7157

N. diseases: 1773; N. variants: 306
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Both tumor phenotypes resulted characterized by a p.E542K point mutation in the PIK3CA gene, whereas adenocarcinoma component revealed also a TP53 Q331* homozygous stop mutation. 28698100 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE DDR2(L63V);TP53(L/L) mice developed poorly differentiated lung adenocarcinomas in all transgenic animals analyzed with a latency of 40 to 50 weeks and a median survival of 67.5 weeks. 26206333 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Seven of 17 cases (41%) were reclassified in the adenocarcinoma with solid pattern group, which showed one KRAS G12C and one EGFR E709K + G719C double mutation in addition to mutations in TP53. 26430808 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE According to the analysis, typical EBV-associated gastric adenocarcinoma constitutes an independent molecular pathological subgroup, which is mutually exclusive to TP53-mutated adenocarcinoma with chromosomal instability, another molecular pathological subtype in gastric adenocarcinomas. 26617924 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE By contrast, mice with both alterations (Hoxb13-MYC∣Hoxb13-Cre∣Pten(Fl/Fl), hereafter, BMPC mice) developed lethal adenocarcinoma with distant metastases and widespread genome CNAs that were independent of forced disruption of Tp53 and telomere shortening. 26554830 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying frequency across molecular subtypes. 25351767 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE IPA analyses showed adenocarcinoma-specific promoter DMxDE overlay identified familiar lung cancer nodes [tP53, Akt] as well as less familiar nodes [HBEGF, NQO1, GRK5, VWF, HPGD, CDH5, CTNNAL1, PTPN13, DACH1, SMAD6, LAMA3, AR]. 26683690 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Nucleotide changes in TP53 were significantly more frequent in adenocarcinoma cases than in squamous cell carcinoma and CIN3 (P = 0.035) and were independent from HPV infection status. 25220666 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Unexpectedly, we found only two cases with TP53 mutation, which is much lower than observed in lung adenocarcinomas in general. 26200269 2016
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras(G12D/+);Trp53(R172H/+) pancreatic ductal adenocarcinomas while increasing their proliferation. 26004068 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE We find very little evidence for dissemination from oncogenic KRAS-driven hyperplasias or most adenocarcinomas. p53 loss is insufficient to drive dissemination but rather enables rare cancer cells in a small fraction of primary adenocarcinomas to gain alterations that drive dissemination. 24740995 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Overexpression of p53 was detected only in high-grade dysplasia and invasive adenocarcinoma. 24603588 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE False-negative controls consisted in microdissecting fresh-frozen tumor tissues both from a patient with a Li-Fraumeni syndrome who carried a p53 constitutional mutation, and from KRas mutated adenocarcinomas. 25184754 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE The authors show that combined loss of autophagy and p53 dramatically promotes progression from early Pancreatic Intraepithelial Neoplasia (PanIN) lesions towards adenocarcinoma and alters the cellular metabolism with an enrichment of anabolic pathway that can fuel the tumor growth. 24939064 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be an indicator of poor prognosis in adenocarcinoma patients; however, its roles and mechanisms in lung squamous cell carcinoma and large cell carcinoma need to be clarified. 25519684 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE We investigated loss of heterozygosity (LOH) and the p53 mutation in 132 lung adenocarcinomas, for which asbestos body burden (AB; in numbers per gram of dry lung) was measured using adjacent normal lung. 24926563 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Strong immunoreactivity of Bcl-2 and mild immunoreactivities of Bax and p53 were detected in ovarian adenocarcinomas. 25108507 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS, BRAF, PIK3CA mutations, and immuno-histochemistry for APC and p53 proteins for normal colon (n=11), hyperplastic polyps (n=11), high grade adenomas (n=10), low grade adenomas (n=34) and adenocarcinoma (n=13). 25496852 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas. 24770931 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas. 24169260 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Fibulin-2 was abundant in the extracellular matrix of human lung adenocarcinomas and was highly expressed in tumor cell lines derived from mice that develop metastatic lung adenocarcinoma from co-expression of mutant K-ras and p53. 23785517 2014
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutations were observed exclusively in four adenocarcinoma components, consistent with their role in the progression from adenoma to adenocarcinoma. 24470207 2014
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Atg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth. 24362353 2014
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE In case 17, mutation took place only in adenocarcinoma cells. p53 mutation was closely related with degree of differentiation, tumor-node-metastasis stage, vessel invasion and lymph node metastasis. 23983439 2014
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE The aims of this study were to determine the expression of p53 protein in endometrial adenocarcinomas (as a potential prognostic indicator before treatment) as well as normal endometrium in imprint smears and to correlate the results with clinicopathologic parameters of primary untreated endometrial cancer patients. 24167025 2014